SOST and osteoporosis: In March 2019, the anti-sclerostin antibody drug romosozumab first became available in clinical practice in Japan for osteoporosis for high-risk fracture cases of osteoporosis (Assessment of Fracture Risk and Its Application to screening for Postmenopausal Osteoporosis, 1994; Soen et al., 2013).